Berning Philipp, Schroer Adrian E, Adhikari Rishav, Razavi Alexander C, Cornelis Francois H, Erinjeri Joseph P, Solomon Stephen B, Sarkar Debkumar, Vargas Hebert Alberto, Schöder Heiko, Fox Josef J, Dzaye Omar
Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Front Oncol. 2024 Feb 9;14:1324095. doi: 10.3389/fonc.2024.1324095. eCollection 2024.
BACKGROUND & AIMS: The treatment options for systemically progressed hepatocellular carcinoma (HCC) have significantly expanded in recent years. In this study, we aimed to evaluate the potential of Google searches as a reflection of prescription rates for HCC drugs in the United States (US).
We conducted an in-depth analysis of US prescription data obtained from the IQVIA National Prescription Audit (NPA) and corresponding Google Trends data from January 2017 to December 2022. We focused on drugs used in the first line and second or later treatment lines for HCC, collecting data on their prescriptions and search rates. Search volumes were collected as aggregated search queries for both generic drugs and their respective brand names.
During the study period from Q1 2017 to Q4 2022, monthly prescriptions for drugs used in HCC treatment showed an 173% increase (from 1253 to 3422). Conversely online searches increased by 3.5% (from 173 to 179 per 10 million searches). Notably, strong correlations were observed between search interest and prescriptions for newer drugs, which indicates increasing usage, while older drugs with declining usage displayed limited correlation. Our findings suggest a growing role of non-physician professions in managing systemically progressed HCC within the US healthcare system, although oncologists remained primarily responsible for drug prescriptions.
In conclusion, online search monitoring can offer the potential to reflect prescription trends specifically related to the treatment of HCC. This approach provides a swift and accessible means of evaluating the evolving landscape of HCC treatment.
近年来,系统性进展期肝细胞癌(HCC)的治疗选择显著增加。在本研究中,我们旨在评估谷歌搜索作为美国HCC药物处方率反映指标的潜力。
我们对2017年1月至2022年12月从IQVIA全国处方审计(NPA)获得的美国处方数据以及相应的谷歌趋势数据进行了深入分析。我们重点关注用于HCC一线治疗和二线或后续治疗的药物,收集其处方和搜索率数据。搜索量以通用名药物及其各自品牌名的汇总搜索查询量来收集。
在2017年第一季度至2022年第四季度的研究期间,用于HCC治疗的药物月度处方量增长了173%(从1253增加到3422)。相反,在线搜索量增长了3.5%(从每千万次搜索173次增加到179次)。值得注意的是,观察到搜索兴趣与新药处方之间存在强相关性,这表明新药使用增加,而使用量下降的旧药相关性有限。我们的研究结果表明,在美国医疗保健系统中,非医生专业人员在管理系统性进展期HCC方面的作用日益增强,尽管肿瘤学家仍主要负责药物处方。
总之,在线搜索监测有潜力反映与HCC治疗相关的处方趋势。这种方法提供了一种快速且可获取的手段来评估HCC治疗不断变化的格局。